A draft knowledge sharing for a potential prospect on revolutionizing the land verification process:

idhubs provides various use cases through its proprietary dApp solutions (decentralized apps) operating on a Hyperledger Fabric infrastructure.

idhubs' Hyperledger Fabric blockchain has the capability to revolutionize the land verification process. With its robust features and seamless integration, it offers a comprehensive solution to address the existing limitations of traditional land registry systems.

By leveraging Hyperledger Fabric, a private blockchain platform known for its reliability and security, idhubs ensures that your land registration process is protected from unauthorized access and fraudulent activities. This platform offers built-in permissions, transaction consensus, and chaincode support, providing a solid foundation for a secure and efficient land registry system.

What sets idhubs' solution apart is its dedication to meeting the specific requirements of land registry systems. With the flexibility to customize the system architecture based on your country's needs, idhubs ensures that the solution seamlessly integrates with your existing land management practices.

idhubs' Hyperledger Fabric-based system encompasses various essential components. These include land document verification, membership service provider, orderer, peer, organization, channel, smart contracts, REST API server, integration with traditional land management systems, mobile verification application, and a web verification portal. This comprehensive approach ensures that every aspect of the land verification process is streamlined, secure, and efficient.

By adopting idhubs' Hyperledger Fabric blockchain capability, you unlock a range of benefits. Experience reduced processing time, enhanced ownership verification, elimination of paperwork and fraud, real-time property title assignment, and fortified security through digital signatures. Enjoy the convenience of a modern and secure land verification system, all backed by the expertise and support of idhubs.

When it comes to revolutionizing land registry systems, idhubs' Hyperledger Fabric blockchain capability is your trusted partner. Embrace the power of blockchain technology, provided by idhubs, to transform your land verification process, increase efficiency, and establish trust and transparency in every step.

#idhubs #LandVerification #blockchain

Building a Web3 Ecosystem for a Midsize Business

Welcome to idhubs…The world’s first digital ecosystem platform. In this article, we will address the importance of SaaS for midsize businesses.

A web3 SaaS all-in-one multilingual ecosystem platform can help midsize businesses differentiate themselves from their competitors and streamline their operations by providing a centralized platform for all their needs. This can help reduce the time and effort required to manage multiple systems and tools and save money by lowering the costs of these systems and tools, as well as IT costs, while improving overall efficiency.

With this type of platform, a midsize business can easily scale and adapt to changing business needs and offer a better customer experience by providing a seamless and consistent familiarity across all channels and languages. It can also provide valuable insights into customer behavior and preferences, helping midsize businesses make data-driven decisions and improve their overall performance.

Having all the necessary tools in one platform saves time training employees on multiple software solutions and reduces the time spent on switching solutions.

Teams can collaborate more effectively, regardless of their location or language. This can help improve communication and productivity, leading to better outcomes.

A midsize business can feel at ease with enhanced security features, such as encryption and multi-factor authentication, to protect sensitive data and prevent unauthorized access.

Find out how idhubs can help grow your midsize business and take advantage of idhubs’ free trial and low cost plans by visiting www.idhubs.com.
#SME #digitaltransformation #ecosystem #go4idhubs

Glenmark Pharmaceuticals on Saturday launched antiviral drug Favipiravir for treatment of mild-to-moderate COVID-19 cases after it received the Indian drug regulator's approval. It will be available under the brand name FabiFlu as a prescription-based medication for Rs 103 per tablet, with recommended dose of 1,800 mg twice a day on day 1 and 800 mg twice a day up to 14th day, according to the Mumbai-headquartered global pharmaceutical company. Glenmark received the approval for manufacturing and marketing Favipiravir from the Drugs Controller General of India (DCGI) on Friday. "The approval has come at a time when cases in India are spiralling, putting tremendous pressure on our healthcare system," Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, said in a statement. "We hope the availability of an effective treatment, such as FabiFlu, will help assuage this pressure considerably and offer patients in India a much-needed and timely therapy option," Saldanha said. Favipiravir is backed by strong clinical evidence, showing encouraging results in patients with mild to moderate Covid-19. It offers broad spectrum RNA virus coverage with clinical improvement noted in 20-90 plus age group. Patients from over 10 leading government and private hospitals were enrolled for the study. Favipiravir could be used for Covid-19 patients with comorbid conditions, like diabetes and heart disease, the company said and added, it would offer rapid reduction in viral load within four days, and faster symptomatic and radiological improvement. Glenmark has developed the active pharmaceutical ingredient (API) and formulation for FabiFlu through in-house R&D team. Glenmark was the first company in India to receive the drug regulator's approval to conduct phase-3 clinical trial of Favipiravir antiviral tablets for Covid-19 patients. Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical, Japan, a subsidiary of Fujifilm Corporation. https://www-nationalheraldindia-com.cdn.ampproject.org/c/s/www.nationalheraldindia.com/amp/story/health%2Fgood-news-glenmark-launches-covid-19-drug-favipiravir-in-india-after-dcgi-approval